| 6.85 -0.115 (-1.65%) | 03-03 16:00 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term | |
|||
| Targets | 6-month : | 9.24 | 1-year : | 10.45 |
| Resists | First : | 7.91 | Second : | 8.94 |
| Pivot price | 7.01 |
|||
| Supports | First : | 6.23 | Second : | 5.18 |
| MAs | MA(5) : | 7.05 |
MA(20) : | 7.04 |
| MA(100) : | 8.74 |
MA(250) : | 8.36 |
|
| MACD | MACD : | -0.4  |
Signal : | -0.5 |
| %K %D | K(14,3) : | 46.9 |
D(3) : | 55.5 |
| RSI | RSI(14): 42.4 |
|||
| 52-week | High : | 14.51 | Low : | 3.75 |
Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and BEARISH in mid-long term.[ ALGS ] has closed above bottom band by 31.1%. Bollinger Bands are 69.5% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 7 bars. This is a sign that the market may be about to initiate a new trend.
| If tomorrow: | Open lower | Open higher |
| High: | 6.95 - 7 | 7 - 7.04 |
| Low: | 6.56 - 6.63 | 6.63 - 6.67 |
| Close: | 6.77 - 6.87 | 6.87 - 6.93 |
Aligos Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses to develop novel therapeutics to address unmet medical needs in viral and liver diseases. Its lead drug candidate is ALG-010133, a s-antigen transport-inhibiting oligonucleotide polymer that is in Phase Ib clinical trial for the treatment of chronic hepatitis B (CHB); and ALG-000184, a capsid assembly modulator, which is in Phase I clinical trials to treat CHB. The company also develops ALG-020572, an antisense oligonucleotide to prevent HBsAg translation and secretion; and ALG-055009, a small molecule THR-ß agonist that is in the Phase 1a/1b for the treatment of non-alcoholic steatohepatitis(NASH). In addition, it develops siRNA drug candidate, ALG-125755, as well as ALG-125097 and ALG-125819, demonstrated potent inhibition of HBsAg release from HBV-infected cells. It has entered into license and collaboration agreements with Luxna Biotech Co., Ltd. to develop and commercialize products containing oligonucleotides targeting hepatitis B virus genome; Emory University to provide hepatitis B virus capsid assembly modulator technology; research, licensing, and commercialization agreement with Katholieke Universiteit Leuven to develop coronavirus protease inhibitors; and Merck to discover, research, optimize, and develop oligonucleotides directed against a NASH. The company was incorporated in 2018 and is headquartered in South San Francisco, California.
Tue, 03 Mar 2026
ALGS Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan
Thu, 26 Feb 2026
Aligos Therapeutics to Announce 4th Quarter 2025 Financial Results on March 5, 2026 - The Manila Times
Mon, 23 Feb 2026
Aligos Therapeutics (ALGS) Reports Encouraging Findings at CROI 2026 - GuruFocus
Mon, 23 Feb 2026
Aligos Therapeutics, Inc. Reports Positive Data from CROI Presentations on Pevifoscorvir Sodium and ALG-097558 - Quiver Quantitative
Mon, 23 Feb 2026
Aligos data hint at high hepatitis B viral suppression, new COVID protease drug - Stock Titan
Thu, 05 Feb 2026
Aligos Therapeutics Appoints New Principal Accounting Officer - The Globe and Mail
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Outperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Underperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Neutral |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 0 (M) |
| Shares Float | 5 (M) |
| Held by Insiders | 3.61e+006 (%) |
| Held by Institutions | 10.3 (%) |
| Shares Short | 241 (K) |
| Shares Short P.Month | 0 (K) |
| EPS | -8.582e+007 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 0 |
| Profit Margin | 0 % |
| Operating Margin | -3 % |
| Return on Assets (ttm) | 827.3 % |
| Return on Equity (ttm) | -54.8 % |
| Qtrly Rev. Growth | 2.65e+006 % |
| Gross Profit (p.s.) | -15.64 |
| Sales Per Share | -53.32 |
| EBITDA (p.s.) | -2.47368e+007 |
| Qtrly Earnings Growth | -13.6 % |
| Operating Cash Flow | 0 (M) |
| Levered Free Cash Flow | -79 (M) |
| PE Ratio | -0.01 |
| PEG Ratio | 0 |
| Price to Book value | 0 |
| Price to Sales | -0.13 |
| Price to Cash Flow | 1.56 |
| Dividend | 0 |
| Forward Dividend | 293580 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|